Le Lézard
Classified in: Health
Subjects: SVY, FDA

New FDA-Approved Nasal Spray Anti-Depressant SPRAVATOtm Now Available in Bay Area at Palo Alto Mind Body


PALO ALTO, Calif., March 14, 2019 /PRNewswire/ --  By age 22, Victor C. had tried everything in his battled against severe depression and was losing hope. Last year he found new hope with intravenous ketamine infusions.  Ketamine lifted his depression. "I felt reborn," he said. "There is no other way to put it. It's indescribable." With the FDA approval of SPRAVATOtm (www.paloaltomindbody.com/services/spravato) ketamine-based nasal spray, others like Victor have new hope in their battle against severe depression.

Victor first benefited from intravenous ketamine infusions administered at Palo Alto Mind Body under the direction of Dr. M Rameen Ghorieshi (www.paloaltomindbody.com/provider/m-rameen-ghorieshi-md-mph).  After initial treatments, Victor transitioned to a maintenance routine involving an off-label ketamine nasal spray. This enabled him to maintain progress made with ketamine infusions and reduce the frequency of booster infusions. FDA's approval of SPRAVATOtm affirms what Victor knows: ketamine-based treatments work.  Furthermore, FDA approval clears the path for patients like Victor to receive support from insurance.

Dr. Ghorieshi, one of the first certified providers of SPRAVATOtm in the Bay Area, is now seeing new patients interested in SPRAVATOtm.   "We've successfully administered over 1000 ketamine treatments to patients with severe depression, anxiety, PTSD, and chronic pain.  The results are tremendously positive," said Dr. Ghorieshi. "This is an amazing opportunity to help a broader range of patients. FDA approval, often followed by insurance coverage, is important to many patients. Additionally, the nasal spray is a great alternative for those uneasy about receiving infusions." 

After more than 1000 IV ketamine treatments (www.paloaltomindbody.com/services/iv-ketamine-infusions), Dr. Ghorieshi reports that 87% of patients have experienced significant improvement and 35% of those consider the improvement to be "life-changing."

In August 2018, Victor hoped to return to college. With ketamine, he took control of his life, returned to school, and finished with a 3.9 average.  "I know many people struggling with depression who don't know what to do. I now have confidence that there's a future," he said.

Palo Alto Mind Body with Janssen CarePath helps patients understand affordable options to seek treatment with SPRAVATOtm including insurance verification and discounts.

Palo Alto Mind Body
550 Hamilton Avenue, Ste. 215
Palo Alto, CA 94301
650-685-2900
www.paloaltomindbody.com

 

SOURCE Palo Alto Mind Body


These press releases may also interest you

at 04:41
AT & IT China 2020, organized by Informa Markets and China Chamber of Commerce for Import & Export of Medicines & Health Products and co-organized by Shanghai Sinoexpo Informa Markets International Exhibition Co., Ltd., to take place at the Shanghai...

at 04:00
Kindful Body, a collaboration of skilled clinicians dedicated to providing compassionate, trauma-informed care for clients suffering from eating disorders, is now offering online eating disorder therapy throughout California. The new virtual group...

at 03:30
TABLE FOR TWO (TFT) USA, a non-profit organization that aims to tackle obesity and global hunger issues, organized its fifth annual social action campaign called ONIGIRI ACTION ? Change the World with Onigiri Rice Balls. The campaign, which...

at 03:22
AT & IT China 2020, organized by Informa Markets and China Chamber of Commerce for Import & Export of Medicines & Health Products and co-organized by Shanghai Sinoexpo Informa Markets International Exhibition Co., Ltd., to take place at the Shanghai...

at 03:05
transcosmos inc., USEN CORPORATION (Headquarters: Tokyo, Japan; President and Representative Director: Kimimasa Tamura), a member of USEN-NEXT GROUP, and OTSUMA WOMEN'S UNIVERSITY (Main Campus: Tokyo, Japan; President: Masanao Itoh) have conducted a...

at 03:02
Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced the outcome of a November 20th meeting with the U.S. Food and Drug Administration (FDA) to discuss a regulatory path forward for...



News published on 14 march 2019 at 14:12 and distributed by: